279 related articles for article (PubMed ID: 19330452)
1. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment.
Casarini AP; Jallad RS; Pinto EM; Soares IC; Nonogaki S; Giannella-Neto D; Musolino NR; Alves VA; Bronstein MD
Pituitary; 2009; 12(4):297-303. PubMed ID: 19330452
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
[TBL] [Abstract][Full Text] [Related]
4. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.
Casarini AP; Pinto EM; Jallad RS; Giorgi RR; Giannella-Neto D; Bronstein MD
J Endocrinol Invest; 2006 Oct; 29(9):826-30. PubMed ID: 17114915
[TBL] [Abstract][Full Text] [Related]
5. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome.
Bronstein MD
Front Horm Res; 2006; 35():129-134. PubMed ID: 16809928
[TBL] [Abstract][Full Text] [Related]
6. Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT/PCR is not associated with the pharmacological response to octreotide.
Gonzalez B; Vargas G; Ramirez C; Asa S; Cheng S; Sandoval C; Mercado M
Endocrinol Nutr; 2014 Dec; 61(10):523-30. PubMed ID: 25008035
[TBL] [Abstract][Full Text] [Related]
7. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
8. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs.
Wildemberg LE; Neto LV; Costa DF; Nasciuti LE; Takiya CM; Alves LM; Rebora A; Minuto F; Ferone D; Gadelha MR
J Endocrinol Invest; 2013 Jan; 36(1):38-43. PubMed ID: 22472799
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
10. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
[TBL] [Abstract][Full Text] [Related]
11. Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly.
Zhang S; Yao S; Chen J; Akter F; Yang J; Zhu D; Zeng A; Chen W; Mao Z; Zhu Y; Wang H
J Neurosurg; 2024 Apr; 140(4):1019-1028. PubMed ID: 37856412
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR responsiveness in acromegaly.
Vieira Neto L; Taboada GF; Gadelha MR
Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1288-95. PubMed ID: 19169483
[TBL] [Abstract][Full Text] [Related]
13. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
14. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern.
Kasuki L; Wildemberg LE; Neto LV; Marcondes J; Takiya CM; Gadelha MR
Eur J Endocrinol; 2013 Aug; 169(2):217-23. PubMed ID: 23749849
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
16. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression.
Muhammad A; Coopmans EC; Gatto F; Franck SE; Janssen JAMJL; van der Lely AJ; Hofland LJ; Neggers SJCMM
J Clin Endocrinol Metab; 2019 Mar; 104(3):915-924. PubMed ID: 30346538
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
Jaquet P; Gunz G; Saveanu A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Enjalbert A; Culler MD
Eur J Endocrinol; 2005 Jul; 153(1):135-41. PubMed ID: 15994755
[TBL] [Abstract][Full Text] [Related]
18. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
19. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
Yang LP; Keating GM
Drugs; 2010 Sep; 70(13):1745-69. PubMed ID: 20731479
[TBL] [Abstract][Full Text] [Related]
20. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
Kubota A; Yamada Y; Kagimoto S; Shimatsu A; Imamura M; Tsuda K; Imura H; Seino S; Seino Y
J Clin Invest; 1994 Mar; 93(3):1321-5. PubMed ID: 8132773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
